Incontinence, Urinary Bladder Cancer, Urinary Incontinence
Conditions
Keywords
Incontinence
Brief summary
In this randomised trial, we hypothesised that mebeverine could enhance nocturnal continenece of Orthotopic Bladder Substitute (OBS) patients by decreasing the frequency and reduce maximum amplitude of uninhibited contractions of OBS ileum, and consequently it would increase the OBS capacity
Interventions
DRUGmebeverine 200 mg sustained-release (Coloverine® SR, Chemipharm pharmaceutical, Egypt) one time/day at the evening.
mebeverine 200 mg sustained-release (Coloverine® SR, Chemipharm pharmaceutical, Egypt) one time/day at the evening. 200 mg sustained-release (Coloverine® SR, Chemipharm pharmaceutical, Egypt) one time/day at the evening.
DRUGPlacebo
Placebo one time/day at the evening.
Sponsors
Mansoura University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* nocturnal enuresis
Exclusion criteria
* daytime incontinence * Orthotopic Bladder Substitute (OBS) reconstruction surgery ≤2 years * chronic kidney disease * local tumor recurrence * adjuvant chemotherapy and/or radiotherapy * chronic retention requiring use of clean intermittent catheterization or indwelling urethral catheterization * suspected or known narrow-angle glaucoma * sensitivity to mebeverine.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| assess the 3-months nocturnal continence rate | 3 months | comparing Urinary function domain from the bladder cancer index (BCI) questionnaire |
Countries
Egypt
Outcome results
None listed